

## IN THE CLAIMS

1. (Original) Use of the 2,5-dihydroxybenzenesulfonic acid or of any of its pharmaceutically acceptable salts for manufacturing of medicines applicable to the treatment of angiodependent diseases.
2. (Original) Use according to claim 1, in which the angiodependent disease also presents a reduction of apoptosis.
3. (Currently Amended) Use according to ~~any of claims~~ claim 1 ~~or 2~~, in which the manufactured medicine is for application in the treatment of cancer.
4. (Original) Use according to claim 3, characterized because the manufactured medicine is used to increase the antiproliferative effect of the cytostatic medicines in the treatment of cancer.
5. (Currently Amended) Use according to ~~any of claims~~ claim 1 ~~to 4~~, characterized because the salt preferred for the manufacturing of the medicine is the potassium salt of the 2,5-dihydroxybenzene sulfonic acid.
6. (Currently Amended) Use according to ~~any of claims~~ claim 1 ~~to 4~~, characterized because the salt preferred for producing the medicine is the calcium salt of the 2,5-dihydroxybenzene sulfonic acid.
7. (Currently Amended) Use according to ~~any of the above claims~~ claim 1 ~~to 6~~ in which the manufactured medicine also includes an adequate amount of at least one pharmaceutically

acceptable excipient.

8. (Original) Use according to claim 1 in which the manufactured medicine is for application in the treatment of psoriasis.

9. (Original) Use according to claim 8, characterized because the salt preferred for production of the medicine is the potassium salt of the 2,5-dihydroxybenzenesulfonic acid.

10. (Original) Use according to claim 8, characterized because the salt preferred for manufacturing of the medicine is the calcium salt of the 2,5-dihydroxybenzenesulfonic acid.

11. (Currently Amended) Use according to ~~any of the above claims~~ claim 8 to 10 in which the manufactured medicine also includes adequate amount of at least one pharmaceutically acceptable excipient.

12. (Currently Amended) Use according to ~~any of the claims~~ claim 8 to 11, characterized because the medicine consists on a topical application formulation.

13. (Currently Amended) Use according to claim 12, characterized because the medicine is a cream or unguent whose composition includes:

- A pharmaceutically efficient amount of the 2,5-dihydroxybenzenesulfonic acid or of any of its pharmaceutically acceptable salts[.];
- A pharmaceutically acceptable amount of at least one alcohol[.];
- A pharmaceutically acceptable amount of at least one

emulsifier[.];

- A pharmaceutically acceptable amount of at least one excipient[.];
- A pharmaceutically acceptable amount of at least one excipient comprising a lipid phase, particularly vaseline;
- Distilled water.

14. (Currently Amended) Use according to claim 13, characterized because the medicine is a cream or unguent that presents a composition that includes:

- 5% of the potassium salt of the 2,5-dihydroxybenzenesulfonic acid
- 2,5% of cetylic alcohol
- 2,5% of stearic alcohol
- 30% of liquid vaseline
- 30% of white soft paraffin
- 5% span (sorbitan oleate)
- q.s 100 g of distilled water.